Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD1208 in Advanced Solid Tumors
NCT06911333Phase 2Recruiting
- Sponsor
- Avelos Therapeutics
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ad-1208 in solid tumor (6 cohorts), sponsored by Avelos Therapeutics. Primary endpoint: Safety and tolerability. Started Mar 2025; status: recruiting.
02
Drugs
ad-1208
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06911333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911333.